循环肿瘤细胞在非小细胞肺癌中的研究进展
|
摘要
循环肿瘤细胞(CTCs)检测作为一种重要的液体活检技术,其检测方法近年来取得了新的发展,同时CTCs在非小细胞肺癌(NSCLC)的诊断、疗效评价、治疗决策、转移或复发的监测等方面也被证明有着重要的价值。本文就近年来国内外的CTCs检测技术及其在NSCLC中的临床应用进展进行综述。
引文
[1]STRILIC B,OFFERMANNS S.Intravascular survival and extravasation of tumor cells[J].Cancer Cell,2017,32(3):282-293.
[2]SHARMA S,ZHUANG R,LONG M,et al.Circulating tumor cell isolation,culture,and downstream molecular analysis[J].Biotechnol Adv,2018,36(4):1063-1078.
[3]SONG P,YE D,ZUO X,et al.DNA Hydrogel with aptamertoehold-based recognition,cloaking,and decloakingof circulating tumor cells for live cell analysis[J].Nano Lett,2017,17(9):5193-5198.
[4]JIANG B Y,LI Y S,GUO W B,et al.Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells[J].Clin Cancer Res,2017,23(18):5480-5488.
[5]YODA S,DAGOGO-JACK I,HATA A N.Targeting oncogenic drivers in lung cancer:Recent progress,current challenges and future opportunities[J].Pharmacol Ther,2019,193:20-30.
[6]CALIFANO R,ABIDIN A,TARIQ N U,et al.Beyond EGFRand ALK inhibition:unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer[J].Cancer Treat Rev,2015,41(5):401-411.
[7]OULHEN M,PAILLER E,FAUGEROUX V,et al.Filteradapted fluorescent in situ hybridization(FA-FISH)for Filtration-enriched circulating tumor cells[J].Methods Mol Biol,2017,1634:133-141.
[8]HAYES D F,CRISTOFANILLI M,BUDD G T,et al.Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival[J].Clin Cancer Res,2006,12(14 Pt 1):4218-4224.
[9]DANILA D C,HELLER G,GIGNAC G A,et al.Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer[J].Clin Cancer Res,2007,13(23):7053-7058.
[10]COHEN S J,PUNT C J,IANNOTTI N,et al.Relationship of circulating tumor cells to tumor response,progression-free survival,and overall survival in patients with metastatic colorectal cancer[J].J Clin Oncol,2008,26(19):3213-3221.
[11]MOON D H,LINDSAY D P,HONG S,et al.Clinical indications for,and the future of,circulating tumor cells[J].Adv Drug Deliv Rev,2018,125:143-150.
[12]MOSTERT B,KRAAN J,BOLT-DE V J,et al.Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146[J].Breast Cancer Res Treat,2011,127(1):33-41.
[13]ONSTENK W,KRAAN J,MOSTERT B,et al.Improved circulating tumor cell detection by a combined EpCAM and MCAMCellSearch enrichment approach in patients with breast cancer undergoing neoadjuvant chemotherapy[J].Mol Cancer Ther,2015,14(3):821-827.
[14]SOLER A,CAYREFOURCQ L,MAZEL M,et al.EpCAM-Independent enrichment and detection of viable circulating tumor cells using the EPISPOT assay[J].Methods Mol Biol,2017,1634:263-276.
[15]BARRIUSO J,CUSTODIO A,AFONSO R,et al.Prognostic and predictive biomarkers for somatostatin analogs,peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours[J].Cancer Treat Rev,2018,70:209-222.
[16]TEWES M,AKTAS B,WELT A,et al.Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer:An option for monitoring response to breast cancer related therapies[J].Breast Cancer Res Treat,2009,115(3):581-590.
[17]AKTAS B,KASIMIR-BAUER S,HEUBNER M,et al.Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy[J].Int J Gynecol Cancer,2011,21(5):822-830.
[18]VONA G,SABILE A,LOUHA M,et al.Isolation by size of epithelial tumor cells:A new method for the immunomorphological and molecular characterization of circulatingtumor cells[J].Am J Pathol,2000,156(1):57-63.
[19]LEDERLIN M,TREDANIEL J,PRIOLLET P.Why screen for lung cancer in patients with arterial disease?[J].J Mal Vasc,2015,40(6):359-364.
[20]LECHARPENTIER A,VIELH P,PEREZ-MORENO P,et al.Detection of circulating tumour cells with a hybrid(epithelial/mesenchymal)phenotype in patients with metastatic non-small cell lung cancer[J].Br J Cancer,2011,105(9):1338-1341.
[21]MAZZINI C,PINZANI P,SALVIANTI F,et al.Circulating tumor cells detection and counting in uveal melanomas by a filtration-based method[J].Cancers(Basel),2014,6(1):323-332.
[22]BAI M,ZOU B,WANG Z,et al.Comparison of two detection systems for circulating tumor cells among patients with renal cell carcinoma[J].IntUrol Nephrol,2018,50(10):1801-1809.
[23]ORTIZ V,YU M.Analyzing circulating tumor cells one at a time[J].Trends Cell Biol,2018,28(10):764-775.
[24]ZHANG T,BOOMINATHAN R,FOULK B,et al.Development of a novel c-MET-Based CTC detection platform[J].Mol Cancer Res,2016,14(6):539-547.
[25]MURLIDHAR V,ZEINALI M,GRABAUSKIENE S,et al.Aradial flow microfluidic device for ultra-high-throughput affinitybased isolation of circulating tumor cells[J].Small,2014,10(23):4895-4904.
[26]KAPELERIS J,KULASINGHE A,WARKIANI M E,et al.The prognostic role of circulating tumor cells(CTCs)in lung cancer[J].Front Oncol,2018,8:311.
[27]LIANG H,HUANG J,WANG B,et al.The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer[J].J Thorac Dis,2018,10(Suppl 7):S838-S845.
[28]LI Y,CHENG X,CHEN Z,et al.Circulating tumor cells in peripheral and pulmonary venous blood predict poor long-term survival in resected non-small cell lung cancer patients[J].Sci Rep,2017,7(1):4971.
[29]JIN X R,ZHU L Y,QIAN K,et al.Circulating tumor cells in early stage lung adenocarcinoma:A case series report and literature review[J].Oncotarget,2017,8(14):23130-23141.
[30]HUR J Y,KIM H J,LEE J S,et al.Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients[J].Mol Cancer,2018,17(1):15.
[31]MARCHETTI A,DEL G M,FELICIONI L,et al.Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing:toward a realtime liquid biopsy for treatment[J].PLoS One,2014,9(8):e103883.
[32]HUANG X,O'CONNOR R,KWIZERA E A.Gold nanoparticle based platforms for circulating cancer marker detection[J].Nanotheranostics,2017,1(1):80-102.
[33]BAYARRI-LARA C,ORTEGA F G,CUETO L D G A,et al.Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection[J].PLoS One,2016,11(2):e148659.
[34]HANAHAN D,WEINBERG R A.Hallmarks of cancer:The next generation[J].Cell,2011,144(5):646-674.
[35]SWANTON C,GOVINDAN R.Clinical implications of genomic discoveries in lung cancer[J].N Engl J Med,2016,374(19):1864-1873.
[36]OHASHI K,MARUVKA Y E,MICHOR F,et al.Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease[J].J Clin Oncol,2013,31(8):1070-1080.
[37]KATAYAMA R.Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase(ALK)-rearranged lung cancer[J].Pharmacol Ther,2017,177:1-8.
[38]NI X,ZHUO M,SU Z,et al.Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients[J].Proc Natl AcadSci U S A,2013,110(52):21083-21088.
[39]BABAYAN A,ALAWI M,GORMLEY M,et al.Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells[J].Oncotarget,2017,8(34):56066-56080.
[40]MENG S,TRIPATHY D,SHETE S,et al.HER-2 gene amplification can be acquired as breast cancer progresses[J].Proc Natl Acad Sci U S A,2004,101(25):9393-9398.
[41]PESTRIN M,BESSI S,GALARDI F,et al.Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients[J].Breast Cancer Res Treat,2009,118(3):523-530.
[42]FEHM T,MULLER V,AKTAS B,et al.HER2 status of circulating tumor cells in patients with metastatic breast cancer:Aprospective,multicenter trial[J].Breast Cancer Res Treat,2010,124(2):403-412.
[43]ILIE M,SZAFER-GLUSMAN E,HOFMAN V,et al.Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer[J].Ann Oncol,2018,29(1):193-199.
[44]WANG Y,KIM T H,FOULADDEL S,et al.PD-L1 Expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer[J].Sci Rep,2019,9(1):566.2019-02-18
[2]SHARMA S,ZHUANG R,LONG M,et al.Circulating tumor cell isolation,culture,and downstream molecular analysis[J].Biotechnol Adv,2018,36(4):1063-1078.
[3]SONG P,YE D,ZUO X,et al.DNA Hydrogel with aptamertoehold-based recognition,cloaking,and decloakingof circulating tumor cells for live cell analysis[J].Nano Lett,2017,17(9):5193-5198.
[4]JIANG B Y,LI Y S,GUO W B,et al.Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells[J].Clin Cancer Res,2017,23(18):5480-5488.
[5]YODA S,DAGOGO-JACK I,HATA A N.Targeting oncogenic drivers in lung cancer:Recent progress,current challenges and future opportunities[J].Pharmacol Ther,2019,193:20-30.
[6]CALIFANO R,ABIDIN A,TARIQ N U,et al.Beyond EGFRand ALK inhibition:unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer[J].Cancer Treat Rev,2015,41(5):401-411.
[7]OULHEN M,PAILLER E,FAUGEROUX V,et al.Filteradapted fluorescent in situ hybridization(FA-FISH)for Filtration-enriched circulating tumor cells[J].Methods Mol Biol,2017,1634:133-141.
[8]HAYES D F,CRISTOFANILLI M,BUDD G T,et al.Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival[J].Clin Cancer Res,2006,12(14 Pt 1):4218-4224.
[9]DANILA D C,HELLER G,GIGNAC G A,et al.Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer[J].Clin Cancer Res,2007,13(23):7053-7058.
[10]COHEN S J,PUNT C J,IANNOTTI N,et al.Relationship of circulating tumor cells to tumor response,progression-free survival,and overall survival in patients with metastatic colorectal cancer[J].J Clin Oncol,2008,26(19):3213-3221.
[11]MOON D H,LINDSAY D P,HONG S,et al.Clinical indications for,and the future of,circulating tumor cells[J].Adv Drug Deliv Rev,2018,125:143-150.
[12]MOSTERT B,KRAAN J,BOLT-DE V J,et al.Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146[J].Breast Cancer Res Treat,2011,127(1):33-41.
[13]ONSTENK W,KRAAN J,MOSTERT B,et al.Improved circulating tumor cell detection by a combined EpCAM and MCAMCellSearch enrichment approach in patients with breast cancer undergoing neoadjuvant chemotherapy[J].Mol Cancer Ther,2015,14(3):821-827.
[14]SOLER A,CAYREFOURCQ L,MAZEL M,et al.EpCAM-Independent enrichment and detection of viable circulating tumor cells using the EPISPOT assay[J].Methods Mol Biol,2017,1634:263-276.
[15]BARRIUSO J,CUSTODIO A,AFONSO R,et al.Prognostic and predictive biomarkers for somatostatin analogs,peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours[J].Cancer Treat Rev,2018,70:209-222.
[16]TEWES M,AKTAS B,WELT A,et al.Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer:An option for monitoring response to breast cancer related therapies[J].Breast Cancer Res Treat,2009,115(3):581-590.
[17]AKTAS B,KASIMIR-BAUER S,HEUBNER M,et al.Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy[J].Int J Gynecol Cancer,2011,21(5):822-830.
[18]VONA G,SABILE A,LOUHA M,et al.Isolation by size of epithelial tumor cells:A new method for the immunomorphological and molecular characterization of circulatingtumor cells[J].Am J Pathol,2000,156(1):57-63.
[19]LEDERLIN M,TREDANIEL J,PRIOLLET P.Why screen for lung cancer in patients with arterial disease?[J].J Mal Vasc,2015,40(6):359-364.
[20]LECHARPENTIER A,VIELH P,PEREZ-MORENO P,et al.Detection of circulating tumour cells with a hybrid(epithelial/mesenchymal)phenotype in patients with metastatic non-small cell lung cancer[J].Br J Cancer,2011,105(9):1338-1341.
[21]MAZZINI C,PINZANI P,SALVIANTI F,et al.Circulating tumor cells detection and counting in uveal melanomas by a filtration-based method[J].Cancers(Basel),2014,6(1):323-332.
[22]BAI M,ZOU B,WANG Z,et al.Comparison of two detection systems for circulating tumor cells among patients with renal cell carcinoma[J].IntUrol Nephrol,2018,50(10):1801-1809.
[23]ORTIZ V,YU M.Analyzing circulating tumor cells one at a time[J].Trends Cell Biol,2018,28(10):764-775.
[24]ZHANG T,BOOMINATHAN R,FOULK B,et al.Development of a novel c-MET-Based CTC detection platform[J].Mol Cancer Res,2016,14(6):539-547.
[25]MURLIDHAR V,ZEINALI M,GRABAUSKIENE S,et al.Aradial flow microfluidic device for ultra-high-throughput affinitybased isolation of circulating tumor cells[J].Small,2014,10(23):4895-4904.
[26]KAPELERIS J,KULASINGHE A,WARKIANI M E,et al.The prognostic role of circulating tumor cells(CTCs)in lung cancer[J].Front Oncol,2018,8:311.
[27]LIANG H,HUANG J,WANG B,et al.The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer[J].J Thorac Dis,2018,10(Suppl 7):S838-S845.
[28]LI Y,CHENG X,CHEN Z,et al.Circulating tumor cells in peripheral and pulmonary venous blood predict poor long-term survival in resected non-small cell lung cancer patients[J].Sci Rep,2017,7(1):4971.
[29]JIN X R,ZHU L Y,QIAN K,et al.Circulating tumor cells in early stage lung adenocarcinoma:A case series report and literature review[J].Oncotarget,2017,8(14):23130-23141.
[30]HUR J Y,KIM H J,LEE J S,et al.Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients[J].Mol Cancer,2018,17(1):15.
[31]MARCHETTI A,DEL G M,FELICIONI L,et al.Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing:toward a realtime liquid biopsy for treatment[J].PLoS One,2014,9(8):e103883.
[32]HUANG X,O'CONNOR R,KWIZERA E A.Gold nanoparticle based platforms for circulating cancer marker detection[J].Nanotheranostics,2017,1(1):80-102.
[33]BAYARRI-LARA C,ORTEGA F G,CUETO L D G A,et al.Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection[J].PLoS One,2016,11(2):e148659.
[34]HANAHAN D,WEINBERG R A.Hallmarks of cancer:The next generation[J].Cell,2011,144(5):646-674.
[35]SWANTON C,GOVINDAN R.Clinical implications of genomic discoveries in lung cancer[J].N Engl J Med,2016,374(19):1864-1873.
[36]OHASHI K,MARUVKA Y E,MICHOR F,et al.Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease[J].J Clin Oncol,2013,31(8):1070-1080.
[37]KATAYAMA R.Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase(ALK)-rearranged lung cancer[J].Pharmacol Ther,2017,177:1-8.
[38]NI X,ZHUO M,SU Z,et al.Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients[J].Proc Natl AcadSci U S A,2013,110(52):21083-21088.
[39]BABAYAN A,ALAWI M,GORMLEY M,et al.Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells[J].Oncotarget,2017,8(34):56066-56080.
[40]MENG S,TRIPATHY D,SHETE S,et al.HER-2 gene amplification can be acquired as breast cancer progresses[J].Proc Natl Acad Sci U S A,2004,101(25):9393-9398.
[41]PESTRIN M,BESSI S,GALARDI F,et al.Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients[J].Breast Cancer Res Treat,2009,118(3):523-530.
[42]FEHM T,MULLER V,AKTAS B,et al.HER2 status of circulating tumor cells in patients with metastatic breast cancer:Aprospective,multicenter trial[J].Breast Cancer Res Treat,2010,124(2):403-412.
[43]ILIE M,SZAFER-GLUSMAN E,HOFMAN V,et al.Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer[J].Ann Oncol,2018,29(1):193-199.
[44]WANG Y,KIM T H,FOULADDEL S,et al.PD-L1 Expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer[J].Sci Rep,2019,9(1):566.2019-02-18